For the quarter ending 2025-09-30, NUVB had -$149,073K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -55,792 | -112,243 |
| Stock-based compensation | 8,021 | 19,885 |
| Depreciation and amortization | 534 | 666 |
| Non-cash lease expense | -54 | 335 |
| Non-cash interest on revenue interest financing agreement | -4,855 | -266 |
| Amortization of debt issuance costs | 317 | 18 |
| Change in fair value of warrant liability | -612 | 297 |
| Amortization of premium on marketable securities | 1,287 | 2,809 |
| Realized (gain) loss on marketable securities | 0 | 2 |
| Net loss on disposal of fixed assets | -30 | -34 |
| Unrealized foreign currency transaction loss | 210 | 205 |
| Acquired in-process research and development | 0 | 0 |
| Accounts receivable | 5,630 | -10,029 |
| Prepaid expenses and other current assets | 669 | 986 |
| Inventory | 5,158 | 552 |
| Interest receivable on marketable securities | 1,543 | 414 |
| Other non-current assets | 846 | -145 |
| Intangible assets | - | 8,000 |
| Accounts payable | -7,059 | 16,071 |
| Contract liabilities | 4,333 | 4,505 |
| Accrued expenses | 8,581 | -8,835 |
| Net cash used in operating activities | -52,889 | -90,805 |
| Cash acquired from anheart acquisition | 0 | 0 |
| Transaction costs related to anheart acquisition | 0 | 0 |
| Purchases of marketable securities | 167,137 | 142,378 |
| Proceeds from sale of marketable securities | 78,528 | 251,689 |
| Cash paid for capitalized market approval intangibles | 8,000 | - |
| Purchases of property and equipment | 12 | 253 |
| Net cash provided by investing activities | -96,621 | 109,058 |
| Proceeds from borrowings, net of debt issuance costs and debt discounts | 0 | 48,901 |
| Proceeds from revenue interest financing agreement | 0 | -150,000 |
| Payments on borrowings | 0 | 700 |
| Payments of debt issuance costs | -11 | 6,607 |
| Payment on revenue interest financing agreement | 68 | - |
| Proceeds from issuance of common stock under espp | 0 | -533 |
| Proceeds from exercises of options | 558 | 1,844 |
| Net cash provided by financing activities | 501 | 193,971 |
| Effect of foreign exchange rate changes on cash and cash equivalents | -64 | 23 |
| Net increase (decrease) in cash and cash equivalents | -149,073 | 212,247 |
| Cash and cash equivalents at beginning of period | 35,723 | - |
| Cash and cash equivalents at end of period | 98,897 | - |
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)